Share on LinkedInShare on LinkedIn

ARTICLE · 26 MARCH 2012

Supreme Court Holds Prometheus’ Diagnostic Method Claim Unpatentable

On March 20, 2012, the United States Supreme Court unanimously reversed the Federal Circuit in a long-awaited decision that may have broad-reaching effects on diagnostic method patents, as well as personalized medicine patents.

United StatesIntellectual Property

Originally published March 21, 2012

On March 20, 2012, the United States Supreme Court unanimously reversed the Federal Circuit in a long-awaited decision that may have broad-reaching effects on diagnostic method patents, as well as personalized medicine patents. At issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. ___ (2012) was whether the correlation between blood levels and optimal dosages of a drug was a patentable process or an unpatentable law of nature. The Court held that Prometheus' claim, which had been twice upheld by the Federal Circuit, was an unpatentable law of nature.

The method claim at issue recited three elements: (1) administering a drug, (2) determining the level of the drug metabolite, and (3) a "wherein" clause that generally notes a metabolite level for dose adjustment. Justice Breyer wrote that despite these steps, "the patent claims [did not] add enough to their statements of the [natural] correlations to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from